Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company specializing in mRNA therapeutics and vaccines, stands at a critical juncture as it navigates a rapidly ...

Shares of Arcturus Therapeutics (ARCT) have gained 7.5% over the past four weeks to close the last trading session at $12.81, ...

SAN DIEGO, May 12, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported its first-quarter 2025 financial results, revealing a significant revenue shortfall and a net loss that missed analyst expectations. Despite the ...

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago. These ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics ARCT, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...